“We sit in the low 60s in terms of Botox share, and that's a clear leadership position by a large margin in the U.S.,” AbbVie COO Jeff Stewart said on the company’s most recent earnings call on Oct.

Evolus, Inc., a pharmaceutical company specializing in aesthetic products, faces significant challenges with its lead product Jeuveau, a treatment for frown lines. Jeuveau's undifferentiated clinical ...

A slowing economy may not trip up Allergan Inc., but competition looms for its key medical cosmetic products. That’s the word of caution from watchers of the Irvine-based drug maker as the new year ...

There’s a new age-defying treatment coming to a dermatology office near you. Rivaling widely popular anti-aging injectables like Botox and Daxxify, the recently FDA-approved neuromodulator Letybo has ...

Botox has become so synonymous with anti-aging wrinkle treatments that many people use the name the same way they refer to tissues as Kleenex. But the brand power has a downside: Competitors have ...

The current stock price likely implies Botox declines, but we think the franchise can maintain healthy growth as a result of expansion of the market and limited price competition. Firms Likely to Have ...

Amid competition from generics and a push to age naturally, Botox sales are slumping. However, its parent company, AbbVie, is not exactly enjoying the same prosperity from the injectable these days as ...

Despite recent economic uncertainties impacting Botox sales, AbbVie anticipates continued strength, even with the emerging competitors. AbbVie's $63 billion acquisition of Allergan in 2020, ...

Investors in Revance Therapeutics Inc. (NASDAQ: RVNC) shouldn’t have much to frown about after the stock gapped up 54.34% on January 9, and built upon those gains in February. Is this a stock to keep ...

Plus, everything you need to know about the needle-free alternatives.